Claim Ledger
Every individual claim pulled out of a comparison — search for a specific number or quote and see exactly which source and perspective it came from, instead of it disappearing into an old article.
379 claims found
- Perspective claimDemocratic
Americans increasingly obtain prescription and unapproved drugs through a "research use only" labeling technicality that keeps sales technically legal, from Vyleesi to unapproved obesity drugs described as being as easy to order "as ordering socks" [S9].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimDemocratic
Compounding pharmacies, which make "personalized" products combining approved drugs with experimental additives, are not regulated by the FDA for safety, quality or efficacy; peptides such as the BPC-157/TB-500 "Wolverine stack" have a cult following among fitness and Silicon Valley communities [S9].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimDemocratic
On the broader innovation question, historical data suggest the FDA is no longer the main barrier to innovation: approval times fell sharply after PDUFA yet new-drug output returned to historical averages, and expedited pathways were driven by drugs "not first in class and thus potentially less innovative" [S10].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimDemocratic
Several studies cited found that since the mid-1990s about 85 to 90 percent of new drugs offered no clinical advantage over existing treatments, implying faster approval does not automatically mean better drugs [S10].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimRepublican
Kennedy, who called himself a "big fan of peptides" on the Joe Rogan podcast and has used them for personal injuries, said he is "very anxious" to make some peptides "more accessible" so "people have access from ethical suppliers" [S3][S15].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimRepublican
The FDA identified peptides used for conditions ranging from insomnia to obesity for potential inclusion on the list of substances that can be safely compounded, at a meeting expected in July [S14].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimRepublican
The reporting notes the counter-case: most peptides have not been reviewed for safety by the FDA, the agency's February advisory said compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug," and Lurie warned "I don't see why one would take the path of proper drug approval if there is now this less rigorous, alternative path to market" [S3][S14].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimRepublican
It frames the current market as a "Wild West" and notes that under the Biden administration the FDA added nearly 20 peptides to the do-not-compound list [S15].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimLibertarian
Peptides fall under overlapping frameworks — full NDA/BLA approval, 503A/503B compounding, "research use only" chemicals, and DSHEA dietary supplements — which shapes how accessible any given peptide is [S1].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimLibertarian
The FDA's three-category bulk substance system determines access: Category 1 permits compounding, Category 2 is under evaluation, and Category 3 placement "effectively restricts access" [S1].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimLibertarian
Specific peptides sit in different positions: BPC-157, CJC-1295 and Ipamorelin remain under review with no FDA-approved equivalent, while the existence of approved versions (e.g., Vyleesi for PT-141) "limits compounding justification" and GLP-1 compounding is tied to active shortage designations [S1].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimLibertarian
Practical guidance for patients emphasizes working with a licensed pharmacy operating under the 503A or 503B frameworks [S1].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimSocialist
A former FDA drug reviewer alleged that managers "corrupted the evaluation of drugs," that reviewers were "told not to question drug companies," and that raising safety concerns triggered retaliation, including a surveillance program targeting agency scientists [S6].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimSocialist
Device-center scientists similarly charged that managers coerced approval recommendations and that unsafe devices were approved as a result, prompting an Office of Special Counsel investigation and congressional scrutiny [S6].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimSocialist
In a separate matter, consumer and environmental groups sued the FDA over its approval of genetically engineered salmon, calling the decision "as unlawful as it is irresponsible" and arguing the agency failed to answer crucial risk questions [S7].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Perspective claimSocialist
No excerpt in this group discusses peptides, compounding, or Section 503A; the third source concerns Eugene Debs and early American socialism and is unrelated to the topic [S8].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Agreement
All perspectives that address peptides agree the evidence base for the substances at issue is limited — most peptides have not been reviewed for safety by the FDA and lack high-quality randomized human trials [S11][S14][S4], a point conceded even by the source arguing the restrictions are overreach, which acknowledges "limited human trials" and reliance on animal and case-series data [S2].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Agreement
There is broad agreement that a largely unregulated grey market exists, driven by "research use only" labeling, and that it poses risks of contaminants, impurities or incorrect doses — described variously as the "Wild West" [S11][S14], as "enormous risk" [S4], and as a technicality Americans rely on to obtain unapproved drugs [S9].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Agreement
Sources across perspectives agree on the factual core: the FDA restricted roughly 14–20 peptides for compounding in 2023 on safety grounds, and in 2026 scheduled a July advisory committee review of seven peptides amid pressure from Secretary Kennedy [S12][S11][S14][S1][S2].
From: How should FDA oversight balance innovation and safety in approving compounded peptides? - Agreement
Multiple sources agree that compounded products are not held to the same FDA review standard as approved drugs — compounding pharmacies are not FDA-regulated for safety, quality or efficacy [S9], and FDA guidance says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug" [S14].
From: How should FDA oversight balance innovation and safety in approving compounded peptides?